Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 April 2021 | Story Financial Aid

Dear Student

Please take note that the NSFAS appeals process is now open.

FIRST TIME AND NEW APPLICANTS

First time1 and new applicants2 for NSFAS funding for 2021 whose applications were rejected by NSFAS must submit their appeal electronically on the MyNSFAS portal. Financial Aid offices may not accept manual forms for this group of students and may not submit manual appeals for this group to NSFAS. You will be able to track your status on the MyNSFAS portal.

SENIOR RETURNING/CONTINUING STUDENTS

Please see appeal form attached.

The following process is ONLY applicable to NSFAS returning/continuing students and exclude first time
and new applicants for NSFAS funding in 2021.

The following documents must be submitted from your “ufs4life” email address for your appeal to be
considered:
  • 1. Completed and signed appeal form attached herewith.
  • 2. Ensure that the relevant box indicating the reason for your appeal is checked.
  • 3. Signed motivation
  • 4. Supporting documents (e.g. Medical certificates, death certificate etc.) Your appeal can
  • unfortunately not be considered in the absence of documentation in support of your reason and
  • motivation for the appeal.
Please note that NSFAS confirmed that you cannot appeal if you exceeded the N+ period. You can only
submit an appeal for one of the reasons provided on the appeal form.

Please submit the abovementioned required documents as one single combined attachment in legible 
PDF format to your campus specific e-mail address below:
Bloemfontein Campus – NSFASAppealsBfn@ufs.ac.za
Qwaqwa Campus – NSFASAppealsQQ@ufs.ac.za
The closing date for submission of appeals is 30 April 2021 at 16:00 and no appeals will be accepted after
this date.

Issued by

Financial Aid

 

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept